Alembic Pharma (APLLTD) Q2 FY27: Revenue +36%, Profit +81%, FY27 Guide 20-25%

Alembic Pharmaceuticals (APLLTD) - Share price: ₹1,041 (screener.in, 21 Nov 2026) - Market cap: ₹20,461 crore (screener.in, 21 Nov 2026) - P/E: 20.1 (screener.in, 21 Nov 2026) - ROCE: 12.3% (screener.in, 21 Nov 2026)

Alembic Pharmaceuticals (APLLTD) raised its FY27 revenue growth guidance to 20-25% after Q2 FY27 profit rose 81% to ₹335 crore.

Alembic Pharmaceuticals Limited makes generic medicines for the US, India and other countries, plus the ingredients (APIs) used in them. The Alembic business was established by the Amin family in 1907. The pharma business was demerged into this listed company in 2010 (the year in its company registration number). It is listed on the NSE and BSE mainboard. The company's presentation shows 9 factories, 283 US generic filings, 209 Indian brands and a field force of 5,800+. The company reports in ₹ billion. This article converts to ₹ crore (₹1 billion = ₹100 crore). It uses the Q2 FY27 investor presentation (4 November 2026) and the earnings call of the same day.

Alembic Pharma Q2 FY27 results: what the investor presentation shows

₹ crore, consolidated Q2 FY26 Q1 FY27 Q2 FY27 Change on year --------------- Revenue from operations 1,910 2,150 2,603 +36% Gross margin 73% 71% 74% (73.7%) +70 bps EBITDA margin 17% 16% 22% +520 bps EBITDA not shown not shown 578 +78% Profit for shareholders 185 173 335 +81% H1 revenue 3,621 4,753 +31% H1 profit for shareholders 339 508 +50%

- All businesses grew by double digits. - R&D spend was 8% of revenue in Q2 FY27 against 10% a year ago. - Management said the margin gain came from "healthy operating leverage in the core business" and from new launches, while it absorbed the planned cost of its US branded business. - Indirect cost lines grew slower than sales: employee cost +15% and other expenses +33%, against revenue +36%.

Alembic Pharma US business: why revenue and profit jumped

₹ crore Q2 FY26 Q2 FY27 Change H1 FY27 H1 change ------------------ India branded 639 725 +14% 1,367 +10% US 566 1,003 +77% 1,781 +64% Ex-US 392 440 +12% 823 +14% API 314 436 +39% 782 +36% Total 1,910 2,603 +36% 4,753 +31%

- US sales are 39% of revenue. On the call, management said US sales without the new launches grew 23% in the quarter. Without bosutinib, Q1 growth was also in the mid-20s. - Bosutinib is a new generic launch with a period of exclusive sales, and it sold far above expectations. The company has exclusivity until the end of November 2026. Management said "what happens after that, I don't know." The FY27 guidance includes the "expected normalization of exclusivity-led sales". - 10 products were launched in H1 FY27 (188 commercialised in all). The US pipeline has 245 approved filings (including 20 tentative) from 283 filed. In Q2 FY27 there were 5 filings and 1 approval. - India branded business: Alembic is ranked 20th in the Indian pharma market with 1.1% share (IQVIA, September 2026). Six brands have crossed ₹100 crore in sales. Its specialty portfolio grew about 17%. Animal health grew 23% to ₹169 crore in Q2. - API: volume-led growth; 153 US drug master files filed in all. - Ex-US: growth led by Europe, helped by Canada and emerging markets including Chile.

What management plans next (its own forward-looking statements)

These are management's own guidance, not facts and not promises.

- FY27 consolidated revenue growth: about 20-25%, raised from the "mid-teens" given last quarter. - US business: up to 40% growth for FY27 (raised). - API business: at least high-teens growth for FY27 (raised). - India branded business: growth in line with the market, close to double digits. Ex-US: mid-teens growth. Both are unchanged. - EBITDA margin: management said the margin profile should hold for the rest of the year (it was about 22% in the quarter). - Gross margin: stay in the 70-75% range it has been in for years. - US branded business (Alembic Therapeutics): a drag of 150-200 basis points on margin for FY27, with breakeven expected from the first half of FY28. Field reps are at about 30-35 against a goal of 40-45. - DifGen Pharmaceuticals partnership: access to 20+ products (patches, complex injectables, eye products) in a US market of about $5 billion. Contributions expected from FY28. - Capex: about ₹250 crore spent in H1. The big spending cycle is over; the company will debottleneck and add lines without large new factories. - Acute (short-term illness) portfolio in India: expected to improve gradually in coming quarters.

Alembic Pharma balance sheet and cash conversion

₹ crore, consolidated 31 Mar 2026 30 Sep 2026 --------- Trade receivables 1,466 1,896 Inventories 2,511 2,654 Trade payables 835 1,159 Borrowings (current + non-current) 1,361 1,490 Cash and equivalents 196 254 Net block (property, plant, equipment) 2,844 2,914 Total equity 5,669 5,937

- Receivables rose 29% in six months against H1 revenue growth of 31%. They equal about 73% of one quarter's revenue at Q2 FY27. - The Q2 presentation has no cash flow statement, so this article does not state cash from operations against profit. - FY26 for reference (company): revenue ₹7,345 crore, EBITDA ₹1,177 crore, net profit ₹675 crore, capex ₹432 crore, EBITDA margin 16%, ROCE 15% (excluding assets not yet in use).

How the valuation compares

Company Share price (₹) P/E Market cap (₹ crore) ROCE --------------- Alembic Pharma 1,040.95 20.1 20,461 12.3% Zydus Lifesciences 1,200.00 26.4 1,19,700 21.1% Cipla 1,415.00 36.8 1,14,316 15.5% Sun Pharma 1,884.90 36.8 4,52,251 20.5% Dr Reddy's 1,390.20 41.5 1,16,119 13.0% Torrent Pharma 4,689.50 82.2 1,78,374 15.2%

Source: screener.in, 21 November 2026. The peers are much larger companies. Alembic has the lowest P/E and also the lowest ROCE of the group. The trailing P/E also still includes quarters before this jump in profit.

Risks

- Part of the US jump came from one-off exclusivity on bosutinib, which ends in November 2026. Management says guidance allows for this fading. - The US is 39% of Q2 revenue, so price falls on US generics hit the whole company. - The US branded business is a margin drag of 150-200 basis points in FY27 and is yet to break even. - Receivables are rising (₹1,466 crore to ₹1,896 crore in six months) and borrowings are ₹1,490 crore. - India branded growth (14% in Q2, 10% in H1) is slower than the group and the "Human Health growth gap vs market" is narrowing but still open. - The company lists regulatory approval, supply and pricing risks in its safe-harbour statement.

The point to remember A 36% jump in sales became an 81% jump in profit because margins widened by 520 basis points. Part of that margin came from a launch whose exclusivity ends this month, so the next two quarters show how much of it stays.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://nsearchives.nseindia.com/corporate/APLLTD04112026143908IntimationInvestorsPresentationS.pdf - https://nsearchives.nseindia.com/corporate/APLLTD10112026163226SEIntimationSubmissionofTranscript.pdf